Nicotinamide Riboside Supplementation and Aging on Altitude Acclimatization

Overview

About this study

The focus of the project is to determine if nicotinamide riboside (NR) supplementation improves the acclimatization process to high altitude. In addition, we will investigate the interaction with aging with a focus on cardio-pulmonary adaptations.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Age 18-90 years
  • Non-smokers
  • Generally healthy
  • English speaking
  • Willing to fund their trip and travel costs to climb Mount Kilimanjaro
  • Signed form stating they have received approval for participation in this study from their primary care provider

Exclusion Criteria:

  • Unable to hike 5-10 miles/day (no orthopedic limitations)
  • Moderate to severe lung disease
  • Insulin dependent diabetes
  • Kidney disease/ renal insufficiency
  • Known history of high altitude pulmonary edema (HAPE) or high altitude cerebral edema (HACE)
  • Pregnant women

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Bruce Johnson, Ph.D.

Closed for enrollment

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20305074

Mayo Clinic Footer